This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kennedy, M. J. Articles by Davidson, N. E. Search for Related Content PubMed PubMed Citation Articles by Kennedy, M. J. Articles by Davidson, N. E.

Administration of Human Recombinant Granulocyte Colony-stimulating Factor (Filgrastim) Accelerates Granulocyte Recovery following High-dose Chemotherapy and Autologous Marrow Transplantation with 4-Hydroperoxycyclophosphamide-purged Marrow in Women with Metastatic Breast Cancer¹

Breast Cancer Program [M. J. K., J. P-C., A. M. H., K. O., N. E. D.] and Graft Engineering Laboratories [J. D., S. J. N.], The Johns Hopkins Oncology Center, Baltimore, Maryland 21287

Stem cell contamination by tumor is common in many diseases for which autologous bone marrow transplantation is used. In in vitro models chemotherapeutic purging reduces contamination and may have an impact on clinical outcome. Purging, however, delays engraftment. Little is known about the ability of granulocyte colony-stimulating factor (G-CSF) to accelerate myelopoiesis after purged autologous bone marrow transplantation. We treated 22 women with metastatic breast cancer with high-dose cyclophosphamide and thiotepa and, following the infusion of 4-hydroperoxycyclophosphamide-purged marrow, administered G-CSF, 16 µg/kg daily, from day 0 to engraftment. Results were compared with a control population of 24 women with breast cancer who received identical chemotherapy and purged marrow but no growth factor. Neutrophll recovery was accelerated in the G-CSF-treated population. An absolute neutrophil count of 500 was reached in 19 days compared with 29 for the historic controls. The median number of days febrile was reduced (8 versus 5.5) as were the number of days of hospitalization from marrow infusion (33 versus 25). There was no difference in the number of days on antibiotics or time to last platelet transfusion. G-CSF was administered without any notable toxicity. G-CSF accelerates myelopoiesis following the infusion of 4-hydroperoxycyclophosphamide-purged autologous marrow and shortens hospitalization.

¹ This study was supported by a research grant from Amgen. M. J. K. and A. M. H. are supported by Grant ACS RD-353 and by National Cancer Institute Grant CA58340-01.

² To whom requests for reprints should be addressed, at Oncology 137, Johns Hopkins Oncology Center, 600 N. Wolfe St., Baltimore MD 21287-8936.

Received 5/13/93. Accepted 9/ 7/93.

This article has been cited by other articles:

				S. M. White, M. H. Alarcon, and D. J. Tweardy Inhibition of granulocyte colony-stimulating factor-mediated myeloid maturation by low level expression of the differentiation-defective class IV granulocyte colony-stimulating factor receptor isoform Blood, June 1, 2000; 95(11): 3335 - 3340. [Abstract] [Full Text] [PDF]

				B. Brockstein and S. Williams High-dose chemotherapy with autologous stem cell rescue for breast cancer: yesterday, today and tomorrow Stem Cells, January 1, 1996; 14(1): 79 - 89. [Abstract]